Mark John Niciu
Assistant Professor of Psychiatry at the University of Iowa
Data updated
Research Footprint
Mark John Niciu appears in 8 tracked papers (2014–2018), most studied alongside Ketamine, across Depressive Disorders, Bipolar Disorder and Major Depressive Disorder (MDD).
Most-cited paper: Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine (467 citations).
Frequent co-authors: Carlos Zarate, David Luckenbaugh and Erica Richards.
Background & Research
Mark J. Niciu, MD, PhD is a psychiatrist at the University of Iowa and an Assistant Professor in Psychiatry. He trained in psychiatry at Yale University and completed neuroscience-focused research fellowships there before joining the University of Iowa, where his clinical interests include mood disorders, addiction medicine, esketamine, ECT, and TMS.
Key Impact
He is a psychiatrist and ketamine researcher whose work helped characterize rapid-acting antidepressant and antisuicidal effects of ketamine in mood disorders.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Mark John Niciu is associated with.
University of Iowa
The University of Iowa is a public research university located in Iowa City, Iowa, United States, founded in 1847. It offers undergraduate, graduate, and professional programs and is known for strong programs in writing, health sciences, and the arts.
View stakeholder →University of Toronto
University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →Mayo Clinic
Multi-campus academic medical center and one of the most recognized healthcare institutions in the world. Mayo Clinic researchers have published evidence reviews on psilocybin-assisted therapy for depression, anxiety, and alcohol use disorder, and have collaborated on ketamine clinical trials — including a biomarker study with the University of Michigan — for treatment-resistant depression.
View stakeholder →